# Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation

> **NCT05032807** · PHASE1 · COMPLETED · sponsor: **King's College London** · enrollment: 14 (actual)

## Conditions studied

- Absorption; Chemicals

## Interventions

- **DRUG:** Standard formulation
- **DRUG:** Novel formulation

## Key facts

- **NCT ID:** NCT05032807
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2022-08-26
- **Final completion:** 2022-09-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05032807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05032807, "Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05032807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*